Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569659 | 0.85 | CFTR (0.47) | CFTRTRPV1CYP3A4CYP2D6 | |
| SCHEMBL15259716 | 0.84 | TRPV1 (0.47) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL15259717 | 0.84 | TRPV1 (0.47) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL9432427 | 0.80 | TRPV1 (0.39) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL28001847 | 0.80 | CFTR (0.47) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL28001848 | 0.80 | TRPV1 (0.46) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL2318940 | 0.80 | CFTR (0.61) | CFTRTRPV1CYP3A4CYP2D6 | |
| SCHEMBL27815869 | 0.79 | TRPV1 (0.41) | TRPV1 | |
| SCHEMBL3318162 | 0.79 | CFTR (0.46) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 | |
| SCHEMBL3318159 | 0.79 | CFTR (0.46) | CFTRTRPV1CYP3A4CYP2D6AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144303-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9556139-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2826774-B1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-9096567-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2826774-A1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | Array Biopharma, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2307397-B1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140221342-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8716498-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140005418-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8569522-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2307397-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158426-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221342-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | HRH1, HRH2, HRH4 | CFTR 2528/4885TRPV1 862/4885CYP3A4 1365/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | CFTR 2155/4885TRPV1 2282/4885CYP3A4 2659/4885 |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD74 | CFTR 1758/4885TRPV1 1912/4885CYP3A4 2642/4885 |
| US-20140005418-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | UGT1A6, UGT2B7, UGT1A7 | CFTR 2851/4885TRPV1 4836/4885CYP3A4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.